The oncogene c-maf is translocated in ‫%01-%5ف‬ of multiple myelomas. Unexpectedly, we observed c-maf expression in myeloma cell lines lacking c-maf translocations and in 50% of multiple myeloma bone marrow samples. By gene expression profiling, we identified three c-maf target genes: cyclin D2, integrin ␤7, and CCR1. c-maf transactivated the cyclin D2 promoter and enhanced myeloma proliferation, whereas dominant inhibition of c-maf blocked tumor formation in immunodeficient mice. c-maf-driven expression of integrin ␤7 enhanced myeloma adhesion to bone marrow stroma and increased production of VEGF. We propose that c-maf transforms plasma cells by stimulating cell cycle progression and by altering bone marrow stromal interactions. The frequent overexpression of c-maf in myeloma makes it an attractive target for therapeutic intervention.
Introduction
Recent work has also demonstrated that interaction of myeloma cells with bone marrow stroma provides the cells with Multiple myeloma, an incurable malignancy of the plasma cell, growth and survival factors such as IL-6 and VEGF and proaccounts for roughly 20% of all hematological malignancies. motes chemotherapeutic drug resistance (Dalton, 2002 ; HidesClues to the pathogenesis of myeloma are coming from two hima and . Although a number of adhesion general approaches, one that focuses on recurrent translocamolecules are present on the surface of multiple myeloma cells, tions and mutations of oncogenes and the other that emphait is not clear which are critical for binding to stromal cells (Cook sizes the interplay between the malignant plasma cells and the et al., 1997). bone marrow microenvironment (Kuehl and Bergsagel, 2002) .
In the present study, we investigated how the oncogene Four recurrent translocations involving the immunoglobulin c-maf contributes to the pathogenesis of multiple myeloma. heavy chain (IgH) locus are likely to be primary oncogenic events c-maf is a member of the basic-leucine zipper family of tranbased on their occurrence in a premalignant lesion termed scription factors that has been shown to be important for IL-4 monoclonal gammopathy of undetermined significance (MGUS) gene expression by T-helper-2 cells (Ho et al., 1996; Kim et al., (Fonseca et al., 2002) , and their use of illegitimate IgH switch 1999a), and formation of the lens (Kim et al., 1999b) . To date, recombination (Kuehl and Bergsagel, 2002) . The t(11; 14) and the molecular targets of c-maf transactivation that are important t(6;14) translocations involve the cyclin D1 and cyclin D3 genes, for malignant transformation in multiple myeloma have not been respectively, and presumably disturb the physiological exit of elucidated. In the present study, we used gene expression proplasma cells from the cell cycle. The t(4;14) translocation deregfiling to identify cyclin D2 and integrin ␤7 as c-maf target genes ulates both the FGFR3 and MMSET genes and the t(14;16) in multiple myeloma, and demonstrate that c-maf increases translocation deregulates the c-maf gene, but the functional consequences of these translocations are unknown. myeloma proliferation and adhesion to bone marrow stroma.
Notably, we found c-maf to be overexpressed and functional into one cell line that expresses c-maf as a consequence of a in roughly one half of myelomas, leading us to propose that t(14;16) translocation (JJN3) (Chesi et al., 1998) . The three genes c-maf is an attractive therapeutic target in this malignancy. that were consistently upregulated by c-maf overexpression and downregulated by Ac-maf were again integrin ␤7, cyclin Results D2, and CCR1, thus confirming that these genes are under the control of c-maf ( Figure 2A ). No genes were consistently Identification of c-maf target genes repressed by c-maf or induced by Ac-maf (data not shown). To gain insight into the mechanism of action of multiple myeloma Ac-maf had no effect on gene expression in two cell lines that oncogenes, we used DNA microarrays to profile gene expresdo not express c-maf (L363 and KMS12; Figure 2A ), demonstrasion in a panel of 28 multiple myeloma cell lines that have been ting the specificity of this dominant negative protein for c-maf. extensively characterized with respect to translocations, gene
As expected from the changes in mRNA abundance, overexcopy number changes, and oncogene mutations (Bergsagel et pression of c-maf increased cyclin D2 and integrin ␤7 protein al., 1996) . Cell lines with translocations of the cyclin D1 and levels ( Figures 2C and 2D ) and Ac-maf decreased integrin ␤7 MMSET/FGFR3 genes expressed these genes more highly than protein levels in c-maf-positive cells ( Figure 2D ). cell lines lacking these translocations (data not shown). UnexTo confirm that these target genes are downstream of c-maf pectedly, c-maf was not only expressed in the 6 cell lines with action, we used siRNA to reduce expression of c-maf mRNA c-maf translocations, but also in cell lines lacking this translocain H929 cells. Quantitative RT-PCR confirmed that c-maf, integtion (data not shown). To confirm and extend this observation, rin ␤7, cyclin D2, and C-C chemokine receptor-1 (CCR1) mRNAs we measured c-maf mRNA levels using a quantitative RT-PCR were knocked down by c-maf siRNA in H929 cells ( Figure 2B ). assay in the 28 cell lines ( Figure 1A ). We found that 13 (46%) c-maf siRNA transduction also decreased surface expression expressed high levels, 3 (11%) expressed low levels, and the of integrin ␤7 ( Figure 2D ). remainder had no detectable c-maf expression. Although c-maf
The cyclin D2 promoter contains a potential c-maf binding expression varied over a wide range, some cell lines lacking a site that matches the consensus c-maf binding (MARE) motif c-maf translocation expressed c-maf as highly as some with and is well conserved in the human and mouse orthologs (Figure a c-maf translocation. It is interesting to note that c-maf is 2C). c-maf was able to directly transactivate a cyclin D2 prooverexpressed in all cell lines with an MMSET/FFGR3 translocamoter construct in transient transfection assays ( Figure 2C ). A tion and one cell line with a cyclin D1 translocation. We also 7 bp mutation that disrupts the key c-maf contact nucleotides detected frequent c-maf expression in primary multiple myof the MARE motif abrogated the ability of c-maf to transactivate eloma cells purified from patient bone marrow aspirates (13/26 the cyclin D2 promoter ( Figure 2C ). These observations provide samples; 50%) ( Figure 1A ), which was surprising since c-maf evidence that cyclin D2 is a direct target of c-maf transactivation. translocations occur in only 5%-10% of myeloma cases (Kuehl and Bergsagel, 2002) . c-maf mRNA was undetectable in normal c-maf augments myeloma proliferation plasma cells purified from bone marrow aspirates, demonstraand tumor formation ting that c-maf overexpression in multiple myeloma is associSince c-maf increased cyclin D2 protein levels ( Figure 2C ), we ated with the malignant process ( Figure 1A) . investigated whether c-maf affected cell cycle progression. RetTo discover potential c-maf target genes, we searched the roviral transduction of c-maf into myeloma cells lacking endogemyeloma cell line gene expression dataset for genes that were nous c-maf expression caused these already cycling cells to differentially expressed between c-maf-expressing and -nonexincrease their division and DNA synthesis ( Figure 3A ). We obpressing cell lines. The three genes that satisfied the selection served no evidence of increased cell death induced by dominant criteria (p Ͻ 0.001; t test) were integrin ␤7, cyclin D2, and C-C negative c-maf (data not shown). This finding is consistent with chemokine receptor-1 (CCR1) ( Figure 1B ). Even cell lines with the idea that the c-maf-driven increase in cyclin D2 levels augrelatively low c-maf expression (e.g., XG-2) expressed these ments entry of cells into the cell cycle. Conversely, in most (6/7) putative c-maf target genes at higher levels than c-maf-negative c-maf expressing myeloma cell lines, introduction of Ac-maf cell lines ( Figure 1B) . We confirmed the coregulation of c-maf decreased their division, including cell lines with and without a and integrin ␤7 in the myeloma cell lines by quantitative RTc-maf translocation ( Figure 3B ). As expected, Ac-maf had no PCR, and also observed this coregulation in the primary multiple effect on the proliferation of two c-maf negative cell lines (Figure myeloma samples ( Figure 1A) . Although a few myeloma cell 3B), again confirming the specificity of this dominant negative lines lacking c-maf expression had low levels of integrin ␤7 protein for c-maf. mRNA, patient samples and normal bone marrow plasma cells Given the effect of c-maf on proliferation in vitro, we tested lacking c-maf expression did not express integrin ␤7 detectably whether tumor formation in vivo by c-maf-expressing myelomas ( Figure 1A) .
was dependent on c-maf ( Figure 4 ). NOD-SCID immunodefiTo directly search for c-maf target genes, we manipulated cient mice were injected intraperitoneally with LP-1 cells that the activity of c-maf in myeloma cell lines and profiled the resulhad been transduced with a retrovirus expressing dominant tant changes in gene expression. Using retroviral transduction, negative Ac-maf or with a control retrovirus. Tumor formation we overexpressed c-maf in two cell lines that have no endogewas assessed by measuring human immunoglobulin in the nous c-maf expression (KMS12 and L363). Additionally, we creblood and by the appearance of visible abdominal masses (Figated a dominant negative form of c-maf, termed Ac-maf, by ures 4A and 4B). All four mice injected with the control LP-1 replacing the basic DNA binding region of c-maf with an acidic cells developed tumors within 26-36 days and had rapidly rising region while retaining the leucine zipper (Olive et al., 1997) . We titers of human immunoglobulin in their blood (Figures 4A and used retroviruses to transduce Ac-maf into two cell lines that express c-maf without a translocation (H929 and LP-1), and 4B). By contrast, the mice injected with dominant negative Ac- maf LP-1 cells either did not form tumors (2/4) or formed tumors c-maf increases myeloma adhesion to bone marrow stroma at a later time point than the mice with control LP-1 cells ( Figure  4B ). Interestingly, the two tumors that arose in mice receiving
Since the interaction of the bone marrow stroma with multiple myeloma cells is an important component of the pathophysiolAc-maf LP-1 cells had little or no expression of Ac-maf protein at the time of sacrifice, unlike the cells that were originally inogy of this malignancy (Anderson, 2001; Shain et al., 2000) , we asked whether the upregulation of integrin ␤7 by c-maf altered jected in these animals ( Figure 4C ). The emergence of these escape tumors, together with the fact that Ac-maf prevented the adhesion properties of myeloma cells. Integrin ␤7 can heterodimerize with either integrin ␣4 or integrin ␣E. Integrin ␣4␤7 tumor formation altogether in 2/4 mice, provides evidence that inhibition of c-maf function blocks the in vivo proliferation of binds to MadCAM-1 and integrin ␣E␤7 binds to E-cadherin (Hynes, 2002 ). E-cadherin has been detected on the surface of c-maf-expressing myelomas. , 2001, 2002) . We therefore investigated E-cadherin-coated plates, whereas two cell lines lacking c-maf whether the enhanced stromal interaction caused by c-maf reexpression (L363 and KMS12) did not bind to E-cadherin-coated sults in increased VEGF secretion ( Figure 5E ). Myeloma cells plates ( Figure 5A ). Retroviral transduction of c-maf into these and stroma cells alone did not secrete appreciable quantities latter cell lines conferred binding to E-cadherin-coated plates of VEGF, but cocultures of stroma with myeloma cells lacking ( Figure 5A ). c-maf expression produced more VEGF (2.3-fold). Even greater Next we investigated the role of c-maf in the interaction of VEGF secretion (5.5-fold) occurred in cocultures of stroma with myeloma cells with bone marrow stromal cells ( Figure 5B ). Cell c-maf-expressing myeloma cells. Again, this augmented VEGF lines expressing c-maf were able to adhere to the stroma, preproduction was dependent upon integrin ␣E␤7 interactions with sumably through the concerted action of several adhesion mole-E-cadherin since antibodies to these two adhesion proteins cules (Anderson, 2001; Shain et al., 2000) . Preincubation of the reduced VEGF secretion to the levels observed using c-maf myeloma cells with an anti-integrin ␤7 antibody resulted in a nonexpressing myeloma cells. These data suggest that c-maf 40%-72% decrease in adherence to the stroma ( Figure 5B) . alters the nature of the myeloma/stromal cell interaction and Preincubation of the stroma with an E-cadherin antibody that interaction leads to an increase in VEGF secretion. blocked adherence of myeloma cells to a similar degree ( Figure  5B ). Myeloma cell lines lacking c-maf expression were able to adhere to stroma, but transduction of these cells with the c-maf Discussion retrovirus increased adherence 2.5-to 3.5-fold ( Figure 5C ). Antibodies to integrin ␤7 or E-cadherin completely blocked the The present analysis of c-maf transcriptional targets in multiple myeloma suggests that c-maf may promote malignant transforincreased adherence caused by c-maf ( Figure 5C ). We developed a competitive binding assay in which fluorescently labeled, mation of plasma cells by at least two distinct mechanisms ( Figure 6 ). One mechanism involves the enhanced proliferation c-maf-negative cells were allowed to adhere to stroma in the presence of increasing numbers of unlabeled cells; c-mafof myeloma cells in a cell autonomous fashion. Plasmacytic differentiation is accompanied by upregulation of the cyclinexpressing cells were more efficient competitors than cells lacking c-maf ( Figure 5D ). These data suggest that c-maf enhances dependent kinase inhibitor, p18 (Tourigny et al., 2002) . Myelomas apparently must circumvent this physiological cell cycle the adhesion of myeloma cells to bone marrow stroma through interactions between integrin ␣E␤7 and E-cadherin.
arrest since two recurrent translocations in myeloma involve the cyclin D1 and cyclin D3 genes, and homozygous deletions of Interaction of myeloma cells with bone marrow stroma induces secretion of vascular endothelial growth factor (VEGF), the p18 locus can occur (Kulkarni et al., 2002) . Our results suggest that the transcriptional activation of cyclin D2 by c-maf which may act in an autocrine and paracrine fashion to promote cyclin D2 promoter. Luciferase activity is indicated as an average of triplicate assays from two independent experiments, with error bars representing the standard deviation. The conserved c-maf binding motif (MARE) in the promoter regions of the human and mouse cyclin D2 gene is shown together with the mutated nucleotides of the mutant cyclin D2 construct. The MARE is located between Ϫ134 and Ϫ122 with respect to the start of translation in the human gene. D: Surface expression of integrin ␤7 is shown for cell lines infected with retroviruses expressing either c-maf or a dominant negative form of c-maf. Surface integrin ␤7 is also shown for H929 cells 72 hr after being transduced with a c-maf siRNA construct. Our results thus identify c-maf overexpression as one of the most frequent oncogenic events in multiple myeloma and establish c-maf as an intriguing novel therapeutic target. Dominant inhibition of c-maf interfered with stromal cell adhesion and proliferation of myeloma cells with c-maf overexpression, whether or not they had a c-maf translocation, and c-maf inhibition blocked tumor formation in immunodeficient mice. Our data predict that an inhibitor of c-maf function would decrease cyclin D2 expression, stromal cell adhesion, and VEGF secretion, thereby inhibiting myeloma proliferation and survival. Total RNA from patient samples was isolated using Trizol (GIBCO-BRL). Lymphochip DNA microarrays were prepared, hybridized, and analyzed as previously described (Shaffer et al., 2000) . Relative gene expression was assessed by comparing a myeloma cDNA probe (labeled with Cy5 dye) with a reference cDNA probe (labeled with Cy3 dye) prepared from a pool of 9 and Weinberg, 2000) since, in many cancers, tumor cells receive lymphoid cell lines, as described (Shaffer et al., 2000) . DNA microarray gene growth and survival signals from stroma (Liotta and Kohn, 2001;  expression data were used to identify genes coregulated with c-maf by tocrine or paracrine fashion to promote myeloma proliferation Flow sorting was used to purify plasma cells from bone marrow aspirates and survival (Bellamy et al., 1999; Dankbar et al., 2000 ; Gupta of myeloma patients (CD138ϩ, CD38ϩ, CD56ϩ) and from normal donor Podar et al., 2001 Podar et al., , 2002 . VEGF may also contribute bone marrow aspirates (CD138ϩ, CD38ϩ, CD19Ϫ). Quantitative RT-PCR to the enhanced bone marrow angiogenesis that is characterisassays (TaqMan) were performed using a one-step reaction solution using tic of myeloma (Anderson, 2001) . the primers shown below for c-maf, integrin ␤7, and USF2 or using primers provided by Assays-on-Demand (Applied Biosystems). The expression of In addition to affecting proliferation and adhesion, c-maf USF2 was detected with the forward primer GGAGCGGCCTGCGATTT, the may also alter the function of myeloma cells by upregulating reverse primer CTTTGAAGGTCTCCTGCATGC, and the probe TCCGGGAG CCR1, a receptor for the chemokine MIP-1␣. Indeed, ectopic TTGCGCCAGACC. Integrin␤7 was detected with the forward primer GAAT expression of c-maf in myeloma cells increased their chemo-CAACCAGACGGTGACTTTCT, the reverse primer GCCCGGAGCCTCA taxis in response to MIP-1␣ (data not shown). Since myeloma GGA, and the probe CAAGCCACCCACTGCCTCCCAG. Expression of c-maf cells from many patients produce MIP-1␣ (Abe et al., 2002;  was detected with the forward primer GCTTCCGAGAAAACGGCTC, the reverse primer TGCGAGTGGGCTCAGTTATG, and the probe CGACAACCC Uneda et al., 2003) , it may be interesting to investigate whether GTCCTCTCCCGAGTTT. The level of c-maf and integrin ␤7 mRNA was deterc-maf regulates autocrine stimulation by MIP-1␣ by upregulatmined by normalization to the level of the control gene USF2, which showed ing CCR1.
Experimental procedures
little variance in expression across all myeloma cell lines assayed.
Our observation that c-maf is overexpressed in roughly half of myeloma cases is surprising given the low frequency of c-maf
